

5/27/2020

Based on NEJM recent publication of the ACTT-1 remdesivir trial for COVID-19 treatment, updated guidance has been provided.

The changes made in guidance are outlined here:

**Old adult criteria:**

- $\leq 10$  days since onset of symptoms
- Receiving one of the following types of respiratory support:
  - $> 6$  liters of supplemental oxygen
  - Non-invasive ventilation
  - Invasive mechanical ventilation
  - Extracorporeal membrane oxygenation (ECMO)

**New adult criteria:**

- One of the following clinical situations:
  - Patient on  $> 4$  liters of supplemental oxygen or non-invasive ventilation AND  $\leq 14$  days since onset of symptoms
  - Patient on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) AND  $< 7$  days since onset of symptoms

**Old pediatric criteria:**

- $\leq 10$  days since onset of symptoms

**New pediatric criteria:**

- $\leq 14$  days since onset of symptoms